Naltrexone does not relieve withdrawal symptoms. In opioid-dependent people, it does the opposite: giving naltrexone before opioids have fully cleared the body triggers a sudden, intense withdrawal that can be worse than letting withdrawal happen naturally. The drug’s actual purpose is relapse prevention, taken after detoxification is already complete, to block the rewarding effects of opioids or reduce alcohol cravings. The confusion is understandable because naltrexone is so closely associated with addiction treatment, but the distinction between managing withdrawal and preventing relapse is critical and sometimes life-threatening.
Why Naltrexone Triggers Withdrawal Rather Than Treating It
Naltrexone is a competitive antagonist at opioid receptors, meaning it latches onto the same receptors that opioids like heroin, fentanyl, or oxycodone use and blocks them.1PubMed Central. Naltrexone: Not Just for Opioids Anymore If someone still has opioids occupying those receptors, naltrexone displaces them all at once. The brain, which has adapted to the constant presence of opioids, is suddenly stripped of them in minutes rather than over the days or weeks a natural withdrawal would take. This abrupt displacement is called precipitated withdrawal, and it can be far more severe than the withdrawal a person would experience simply by stopping opioid use.
The severity depends on several factors. Research on heroin-dependent individuals found that the amount of heroin used before the procedure and the number of hours since the last dose both independently predicted how bad the withdrawal would be.2PubMed. Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity People who used more heroin, or who used it closer to the time naltrexone was introduced, experienced worse symptoms. In that study, while most participants eventually completed withdrawal, almost half were too symptomatic to start naltrexone maintenance on the planned day.
What Precipitated Withdrawal Can Do
Precipitated withdrawal shares the same symptoms as ordinary opioid withdrawal (nausea, vomiting, diarrhea, muscle aches, sweating, agitation) but with a sharper onset and, in some cases, dangerous complications. Case reports involving the long-acting injectable form of naltrexone illustrate the extremes. In one case, a woman who received the injection after relapsing on opioids developed a hypertensive emergency requiring continuous intravenous medications and intensive-care monitoring. In another, a man who had been secretly using heroin during a detox program became severely agitated with altered mental status after receiving the injection.3PubMed. Severe opioid withdrawal precipitated by Vivitrol® The injectable form poses a particular risk because it cannot be removed once administered; it slowly releases naltrexone over about a month, meaning the precipitated withdrawal can last much longer than it would with a single oral dose.
This is why naltrexone carries a clear requirement: patients must be fully detoxified and opioid-free before starting the medication. When that rule is followed, naltrexone itself produces few withdrawal-like symptoms. The danger is entirely about timing.
The Mandatory Waiting Period
Standard protocols require that a person be free of short-acting opioids for at least seven days, and free of longer-acting opioids like methadone for ten to fourteen days, before the first dose of naltrexone. In clinical trials, a common approach involves a buprenorphine taper over roughly a week followed by an additional week-long wait before administering injectable naltrexone.4PubMed Central. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine That waiting period is the most vulnerable window in opioid treatment. The person is no longer taking opioids, hasn’t yet started naltrexone, and is dealing with uncomfortable withdrawal. Many people relapse during this gap, which is one reason naltrexone can be hard to start in practice.
Some clinicians use a small oral test dose of naltrexone before giving the injection. If the patient tolerates it without withdrawal symptoms, that confirms opioids have cleared the system. One feasibility trial used a rapid titration approach, starting with a very small oral dose of about 6 mg on the first day after buprenorphine discontinuation and working up from there. Participants in that trial actually saw their withdrawal scores decrease rather than increase after the first oral naltrexone dose, and all were able to transition successfully to injectable naltrexone.5PubMed. Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial Approaches like this aim to shorten that risky gap, though they still require careful medical supervision.
Very Low Dose Naltrexone During Detox
One genuinely interesting twist in the research involves using extremely small doses of naltrexone, far below the standard treatment dose, alongside opioid taper programs. The logic seems paradoxical: if standard-dose naltrexone causes withdrawal, why would any amount of it help during detox? The answer appears to lie in how the opioid system responds to very low levels of receptor blockade, which may gently reset receptor sensitivity without producing the abrupt displacement that causes precipitated withdrawal.
A randomized controlled trial tested daily doses of 0.125 mg and 0.250 mg of naltrexone (the standard therapeutic dose is 50 mg, so these are roughly 200 to 400 times smaller) during opioid detoxification. Both low-dose groups reported significantly lower withdrawal scores than the placebo group.6PubMed Central. Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial An earlier pilot study of five patients on a methadone taper with very low dose naltrexone found that the treatment was completed without incidents or particular discomfort, and all patients transitioned to naltrexone maintenance by discharge.7PubMed. Use of very low-dose naltrexone during opiate detoxification
This is still a niche area of research, and very low dose naltrexone for detox is not part of mainstream clinical guidelines. But it represents the one scenario in which naltrexone, at tiny doses, might genuinely ease withdrawal rather than cause it. The distinction between micro-dosing during detox and standard dosing for relapse prevention matters enormously.
Ultra-Rapid Detox Under Anesthesia
You may have heard of “rapid” or “ultra-rapid” opioid detox programs that put patients under general anesthesia and then administer large doses of opioid antagonists, essentially forcing the body through the entire withdrawal process while the person is unconscious. The idea was to compress days of misery into a few hours that the patient would sleep through, then wake up ready for naltrexone maintenance.
The reality has been far messier. A review of the procedure acknowledged that while it allows a person to withdraw without consciously experiencing the discomfort, the sympathetic nervous system response can be dangerous if not properly managed.8PubMed. Ultrarapid opiate detoxification: a review A randomized trial comparing anesthesia-assisted detox to buprenorphine-assisted or clonidine-assisted approaches found that three patients in the anesthesia group experienced serious adverse events, including one who developed severe pulmonary edema and aspiration pneumonia requiring reintubation and five days in intensive care.9JAMA. Anesthesia-Assisted vs Buprenorphine- or Clonidine-Assisted Heroin Detoxification and Naltrexone Induction: A Randomized Trial Another patient in that trial developed diabetic ketoacidosis shortly after discharge. Research on heroin users undergoing antagonist-precipitated withdrawal under anesthesia found that for a substantial proportion of participants, the process was “neither rapid nor painless,” with many experiencing significant residual withdrawal after waking.2PubMed. Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity
Most addiction medicine organizations now discourage ultra-rapid detox because the risks of anesthesia add to the already dangerous physiology of precipitated withdrawal, without clearly improving long-term outcomes compared to slower, safer approaches.
What Naltrexone Actually Does After Withdrawal
Once a person has made it through detoxification and has been opioid-free long enough, naltrexone’s real value begins. By occupying opioid receptors without activating them, it ensures that if the person uses opioids again, they feel little or no euphoria. This removes the reinforcing effect that drives repeated use. It doesn’t eliminate cravings on its own in the way that buprenorphine or methadone can, but it makes acting on a craving unrewarding.
The injectable form has shown a clear advantage over daily pills. A randomized trial found that patients receiving monthly injections were roughly twice as likely to remain in treatment at six months compared to those taking oral naltrexone (about 57% versus 28%).10PubMed Central. A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder The reason is straightforward: you cannot skip a dose that was injected into your muscle a week ago. With daily pills, a person who starts experiencing cravings can simply stop taking them, wait a day or two for the blockade to weaken, and use opioids again.
How Naltrexone Stacks Up Against Other Opioid Medications
Naltrexone occupies a different niche than methadone and buprenorphine. Those two are agonist treatments: they activate opioid receptors enough to prevent withdrawal and reduce cravings, without producing the intense high of illicit opioids. Naltrexone is a pure antagonist: it blocks receptors entirely. This difference has practical consequences for retention. An analysis of Medicaid data found that patients on naltrexone had a higher risk of dropping out compared to both methadone and buprenorphine, and that gap widened over the course of a year.11PubMed. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data A systematic review and meta-analysis placed naltrexone fourth among opioid use disorder medications for treatment retention, behind methadone, slow-release oral morphine, and buprenorphine.12Frontiers in Psychiatry. The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis
Naltrexone also appears less protective against overdose during active treatment. A study of commercially insured patients found that buprenorphine was associated with a significant reduction in opioid-related overdose risk compared to no treatment, while neither injectable nor oral naltrexone showed a statistically significant protective effect.13PubMed Central. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort There is also a well-known concern that after naltrexone wears off or is stopped, a person’s opioid tolerance will have dropped, making them vulnerable to overdose if they return to their previous dose.
None of this means naltrexone is a poor medication. For people who have completed detox, are motivated to avoid agonist treatments, or are in settings like the criminal justice system where opioid agonists are restricted, naltrexone can be effective. The point is that it works best for a specific patient profile and requires getting through detox first, which is the exact opposite of treating withdrawal.
Naltrexone and Alcohol Withdrawal Are Also Different Things
Naltrexone is FDA-approved for alcohol use disorder, which creates another layer of confusion. People sometimes assume it helps with alcohol withdrawal. It does not. Alcohol withdrawal can involve seizures, delirium tremens, and other medically dangerous symptoms that require benzodiazepines and close monitoring. Naltrexone has no role in that acute phase.
What naltrexone does for alcohol is reduce craving and the pleasurable effects of drinking after the acute withdrawal phase is over. In laboratory settings, naltrexone-treated participants drank fewer drinks, consumed them more slowly, and reported lower craving compared to those on placebo.14PubMed. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis Clinical trials have shown that at a dose of 100 mg daily, naltrexone produced an absolute increase of about 15 percentage points in good clinical outcomes compared to placebo.15PubMed Central. Naltrexone for the Management of Alcohol Dependence Adding behavioral therapy to naltrexone also appears to strengthen results: data from a large trial found that the combination increased the probability of following a trajectory where drinking frequency declined over time.16PubMed Central. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study
The mechanism involves the brain’s endorphin system. Alcohol triggers endorphin release, which activates opioid receptors and contributes to the rewarding feelings of drinking. By blocking those receptors, naltrexone dampens the payoff. Research has linked this effect specifically to kappa opioid receptor activity: participants on naltrexone reported lower craving scores and consumed fewer drinks during controlled drinking sessions.17PubMed. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving Over time, if drinking consistently fails to produce the expected reward, the drive to drink weakens.
Naltrexone for Methamphetamine and Other Stimulants
Researchers have explored whether naltrexone’s reward-blocking properties extend to stimulants like methamphetamine, which act on different brain pathways but still involve opioid system cross-talk. A lab study found that naltrexone blunted cue-induced craving for methamphetamine and reduced subjective feelings of stimulation and desire for the drug during controlled administration.18Neuropsychopharmacology. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study A clinical trial combining injectable naltrexone with bupropion found a modest treatment effect over 12 weeks: about 14% of the combination group responded, compared to about 3% on placebo.19PubMed Central. Bupropion and Naltrexone in Methamphetamine Use Disorder
However, a systematic review and meta-analysis looking at naltrexone alone for amphetamine-type stimulant use disorders found no significant difference from placebo in stimulant use, study retention, end-of-treatment craving, or serious adverse events.20Journal of Addiction Medicine. Is Naltrexone Effective and Safe for Treating Amphetamine-Type Stimulant Use Disorder? A Systematic Review and Meta-analysis The current picture suggests naltrexone might contribute something in combination with other medications for methamphetamine use, but it isn’t effective on its own for stimulant withdrawal or craving reduction.
Naltrexone During Pregnancy
Buprenorphine and methadone are the standard-of-care medications for opioid use disorder during pregnancy, partly because they prevent the cycles of withdrawal that can harm the fetus. Naltrexone’s role in pregnancy has been less studied, but emerging data is cautiously encouraging for women who are already stabilized on it or who prefer a non-agonist approach.
A study comparing naltrexone-treated pregnant women with those on buprenorphine found that the rate of neonatal abstinence syndrome (withdrawal symptoms in newborns) was dramatically lower in the naltrexone group: about 8% versus 75%. Among women who received naltrexone all the way through delivery, no neonates experienced withdrawal symptoms at all. Rates of birth anomalies and other obstetric outcomes did not differ between groups.21PubMed. Use of naltrexone in treating opioid use disorder in pregnancy A smaller case series similarly reported no fetal anomalies and no neonatal opioid withdrawal syndrome among infants born to women treated with naltrexone during pregnancy.22PubMed Central. Case series of individuals treated with naltrexone during pregnancy for opioid and/or alcohol use disorder
The challenge remains the same one that exists outside of pregnancy: starting naltrexone requires being opioid-free first, and withdrawal during pregnancy carries its own risks. These studies involved women who were carefully managed through detoxification before receiving naltrexone. Naltrexone is not a tool for treating withdrawal in pregnant women any more than it is for anyone else.
Low-Dose Naltrexone for Chronic Pain and Inflammation
Entirely separate from addiction medicine, naltrexone at very low doses (typically 1 to 5 mg, compared to the standard 50 mg) has attracted attention for chronic pain and inflammatory conditions. At these doses, naltrexone interacts with Toll-like receptor 4 on immune cells called microglia, producing anti-inflammatory and potentially analgesic effects through a pathway that doesn’t even involve opioid receptors.23PubMed Central. The use of low-dose naltrexone LDN as a novel anti-inflammatory treatment for chronic pain Research has explored low-dose naltrexone for conditions ranging from fibromyalgia to autoimmune diseases and even as an adjunct in cancer therapy.24PubMed. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy
This use is almost entirely off-label and the evidence base is still thin, consisting mostly of small trials and case reports. But it is worth knowing about because people searching for information about naltrexone and symptom relief may encounter low-dose naltrexone communities online, and the claims can be confusing. Low-dose naltrexone for pain operates through a completely different mechanism than standard-dose naltrexone for addiction, and its ability to manage inflammatory symptoms has nothing to do with opioid withdrawal. The two should not be conflated, even though they involve the same molecule.
Liver Safety and Monitoring
Naltrexone’s prescribing information includes a boxed warning about potential liver toxicity, which dates back to early studies that used doses several times higher than what is currently standard. At the approved doses, clinically significant liver damage appears rare, but monitoring is still recommended. A review of the literature concluded that naltrexone can be a safe option for alcohol use disorder patients but emphasized that liver function tests should be checked regularly.25Journal of Liver Research, Disorders & Therapy. Liver toxicity of Naltrexone. a case study and review of literature This matters particularly for people with alcohol use disorder, who often already have some degree of liver compromise. Most clinicians check liver enzymes before starting naltrexone and periodically afterward, adjusting or stopping the medication if values climb significantly.